Ph: (740) 356-7490 Fx: (740) 356-7488

Risankizumab-rzaa (Skyrizi) Order Form

		PATIENT	& PRESCRIE	BER INFORMATION	
Patient Name:		[OOB:	Phone: (H)	(C)
Patient Address:					
Duranila a Nama /Titla			ا ـ ا ـ ا		
Phone:	Fa:	κ:		Prescriber NPI #:	
			· ·	-	established with SOMC. Supporting clinica cations to conventional therapy.
	DIA	GNOSIS, CLIN	IICAL INFOR	MATION, & PRESCR	IPTION
☑ May substitute mand	ated or preferre	d biosimilar as n	ecessary.		
Infusion rates will fol	ow manufactur	er recommendati	ons.		
					AIC established protocols will be utilized.
	rse events post	administration fo	or at least 30 m	inutes or until clinically s	table.
	•			red 30 minutes prior to	each administration.
☐ Acetaminophen (Ty	lenol) 650 mg b	y mouth x 1 dos	e		
\square 25 mg / \square 50 mg D	iphenhydramin	e (Benadryl) 🗌 F	°O or □ IV x 1	dose	
☐ Methylprednisolon	e (Solumedrol)	100 mg IVP x 1 d	ose		
☐ Other (Please Speci	fy) -				
			ANI		
Diagnosis (Check all tha	t apply)				
☐ Crohn's Disease					
Induction Dose:					
☐ Risankizumab (Sky	rizi) 600 mg IV v	veek 0, week 4, an	d week 8 (Q28E	x3 doses)	
☑ 0.9% NS 250 mL p			•	•	
Maintenance Dose	-				
☐ Risankizumab (Sky		Q at week 12 and	every 8 weeks >	(6 (1 year)	
☐ Risankizumab (Sky	rizi) 360 mg Sub	Q at week 12 and	every 8 weeks	x6 (1 year)	
			OR		
<u>Diagnosis</u>					
☐ Psoriatic Arthr	tis 🗆	Plaque Psoriasis	S		
Dose:		·			
☐ Risankizumab (Sky	rizi) 150 mg Suh	O week O week 4	and then every	12 weeks v4 (1 year)	
☐ Risankizumab (Sky			•	12 Weeks A4 (1 year)	
	,	~ ~===	-,		
□ Manikizullian (ak					
Additional order(s)					
Additional order(s) Lab order(s)					
Additional order(s) Lab order(s) CBC	at each dose	or □ every			
Additional order(s) Lab order(s) CBC CBC w/ Diff	at each dose	or			
Additional order(s) Lab order(s) CBC CBC w/ Diff	at each dose	or □ every			



Created: 02/28/24	P & T Comm.
Reviewed & Approved	02/29/24
Next Review Date	02/28/26
Version	V02292024.0